"10.1371_journal.pone.0024369","plos one","2011-09-08T00:00:00Z","Paul McCrone; Christine Anne Mary Payan; Martin Knapp; Albert Ludolph; Yves Agid; P Nigel Leigh; Gilbert Bensimon; for the NNIPPS Study Group ¶","Health Service and Population Research Department, Institute of Psychiatry, King's College London, London, United Kingdom; APHP, Département de Pharmacologie Clinique, Hôpital de la Pitié-Salpêtrière, UPMC Pharmacologie, Paris 6, UMR 7211, Paris, France; Personal Social Services Research Unit, London School of Economics, London, United Kingdom; Department of Neurology, University of Ulm, Ulm, Germany; ICM (Brain and Spine Institute), Hôpital de la Pitié-Salpêtrière, Assistance Publique Hôpitaux de Paris & UPMC Université Paris 06, Paris, France; Brighton and Sussex Medical School, Trafford Centre for Biomedical Research, University of Sussex, Falmer, Brighton, United Kingdom","Conceived and designed the experiments: PM CP MK AL YA PNL GB. Performed the experiments: PM CP. Analyzed the data: PM CP. Wrote the paper: PM CP MK AL YA PNL GB.","Pr. Y. Agid serves as consultant for Servier. Pr. A. C. Ludolph serves on Scientific Advisory Boards for Lundbeck, F. Hoffmann La Roche, Knopp Neurosciences. Received funding for travel expenses and/or honoraria for lectures from Boehringer-Ingelheim, Teva, ComtecMed, Lundbeck, Sanofi, ONO, Santhera, Schwarz Pharma, GlaxoSmithKline, Bayer Vital and Sanofi. Pr. P.N. Leigh has received payments for consultancy from GlaxoSmithKline, Acceleron pharma, NeuroNova, Trophos, and Teva and has received funding for clinical trials from GlaxoSmithKline, Teva, ONO Pharma, Trophos, and Sanofi-Aventis. Dr. G. Bensimon is presently consultant for LTK-pharma, Allon pharma and TauRx pharma, and received funding for trial-related travel expenses from SANOFI-AVENTIS. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.","2011","09","Paul McCrone","PMC",8,TRUE,7,2,2,7,TRUE,TRUE,TRUE,1,"8",TRUE
